Neural Dimensions of Attention Bias Modification for Transdiagnostic Anxiety

点击翻译按钮获取中文摘要

DESCRIPTION (provided by applicant): Current first-line treatments for clinical anxiety exhibit a 50-70% response plateau, with high rates of relapse, low rates of remission, and little evidence to suggest which patients may benefit from which treatment options. Barriers to progress towards a more efficient and effective approach to psychiatric care may include inadequate focus on theory-driven, mechanistic predictors of treatment outcome; the use of heterogeneous treatment protocols that require expert administration and have multiple likely mechanisms; and the current diagnostic nosology of psychiatry, which may obscure critical, transdiagnostic dimensions of biobehavioral functioning. The candidate's long-term ambition is to improve outcomes in clinical anxiety treatment through an increased focus on transdiagnostic dimensions of neurocognition. Such work has the potential to 1) guide refinement and development of novel mechanistic, "neurobehavioral" treatment approaches, or treatments that target brain mechanisms through behavioral methods, and 2) fine-tune the clinical indications of specific approaches, e.g., by characterizing the specific aspects of anxiety pathophysiology that are (and are not) targeted by specific neurobehavioral treatments. The candidate's immediate focus is to study neural mechanisms of excessive attention to threat and target these mechanisms directly using a computer-based training intervention, attention bias modification (ABM). Excessive attention to threat is theorized to be a critical contributor to chronic anxiety symptoms and related negative health consequences. ABM, which directly targets this mechanism, is a highly cost-effective intervention with rapidly growing empirical support for its efficacy in clinically anxious populations. The candidate seeks to bridge basic and applied research domains by investigating neural mechanisms of threat processing in anxiety and relating these neural dimensions to ABM outcome. The current Mentored Patient Oriented Career Development Award will uniquely position the candidate to advance her long-term research agenda. Her background includes specialized training in neural mechanisms of attention to threat in anxiety, basic fMRI methods, and preliminary exposure to neurobehavioral treatment research, in addition to broad training in clinical psychology, statistics, research methods, and cognitive- affective neuroscience. She seeks to deepen, extend, and integrate across her previous training, receiving additional training in 1) neural circuitry of threat processing; 2) advanced fMRI methods; and 3) clinical trials research-including basic methods for testing efficacy and advanced methods for testing neural mechanisms and predictors of outcome. The University of Pittsburgh is an outstanding environment in which to engage in the interdisciplinary training required to achieve these training goals. The candidate's mentors-Greg Siegle (University of Pittsburgh), David Brent (University of Pittsburgh), and Nader Amir (San Diego State University)-have combined expertise in advanced fMRI methods, neural and attentional mechanisms of anxiety and threat processing, clinical trials research, neurobehavioral treatments, and neural predictors and mechanisms of treatment outcome. The team's collective record of individual productivity, strong mentorship histories, and interdisciplinary collaboration makes them ideally suited to guide the candidate's trajectory. The proposed project draws on this training and expertise to examine two dimensions of attention to threat: initial vigilance and sustained bias towards threat. The proposed study will examine the neural correlates of each form of threat processing using an individual differences, transdiagnostic approach. 65 individuals with clinically disabling trait anxiety will complete fMRI tasks designed to capture these dissociable dimensions, as well as behavioral, self-report, and diagnostic measures. Participants will be randomly allocated to receive ABM (n=45), which is specifically designed to ameliorate initial vigilance to threat, or a sham intervention (n=20). A subset of ABM completers (n=20) will repeat fMRI assessments post-intervention. Data will be used to test a neural mechanistic model of ABM efficacy which posits that initial, but not sustained, neural processing of threat will be specifically targeted by ABM. Accordingly, the candidate will examine 1) neural mechanisms correlated with behavioral manifestations of initial and sustained attention to threat at baseline; 2) ABM effects on symptom-level, behavioral, and neural dimensions of initial and sustained threat processing; and 3) associations between baseline neural dimensions and ABM outcomes. These analyses will give the applicant valuable experience using an individual differences approach to understand anxiety pathophysiology and outcomes following a mechanistic treatment. They will also provide pilot data for future work in programmatic neurobehavioral treatment research. Future large-scale R01 studies will be designed to, e.g., further validate identified neural dimensions of threat processing as moderators and mediators of treatment outcome, translate fMRI predictors into clinically available forms, and develop new neurobehavioral approaches designed to target predictors of ABM non-response. Consistent with NIMH's Strategic Plan Strategy 1.4 and proposed Research Domain Criteria, the ultimate goal of this work is to promote a neurocognitive process-based framework for more effective patient classification and treatment.